Last reviewed · How we verify

Placebo to ozanimod — Competitive Intelligence Brief

Placebo to ozanimod (Placebo to ozanimod) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Sphingosine-1-phosphate (S1P) receptor modulator. Area: Immunology.

phase 3 Sphingosine-1-phosphate (S1P) receptor modulator S1P1 and S1P5 receptors Immunology Small molecule Live · refreshed every 30 min

Target snapshot

Placebo to ozanimod (Placebo to ozanimod) — Celgene. Ozanimod is a selective sphingosine-1-phosphate (S1P) receptor modulator that reduces lymphocyte egress from lymphoid tissues, decreasing circulating lymphocytes and inflammatory cell infiltration into affected tissues.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Placebo to ozanimod TARGET Placebo to ozanimod Celgene phase 3 Sphingosine-1-phosphate (S1P) receptor modulator S1P1 and S1P5 receptors

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Sphingosine-1-phosphate (S1P) receptor modulator class)

  1. Celgene · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Placebo to ozanimod — Competitive Intelligence Brief. https://druglandscape.com/ci/placebo-to-ozanimod. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators: